Summary
Psychiatric disorders associated with changes in female sex hormones are a major public health issue and represent a unique opportunity to study the complex interplay between gender, sex and mental states. GASSP aims to understand how genetic and environmental markers can help identify women at risk of psychiatric disorders in relation to the menstrual cycle, childbirth and transition to menopause and improve the current approach to diagnosis, prevention and treatment. It takes a ground-breaking approach across diagnoses and life stages, rather than focussing on the current diagnostic labels that have limited clinical and biological validity. It seeks to characterise the largest cohort to date of women with psychiatric disorders temporally related with changes in sex hormones by leveraging new technologies a) to identify and reach sufferers, making it easier for them to participate in research b) to conduct sophisticated analyses, integrating detailed longitudinal clinical and psycho-social information with aggregated genome-wide data and functional annotations. GASSP is the first molecular genetic study of the psychiatric sensitivity to sex hormone changes. It has the potential to contribute to the de-stigmatization of mental disorders related to female reproduction by providing evidence-based, easy-to-understand information to the public, and addressing the gender gap in psychiatry highlighted by the European Commission and the World Health Organization.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/947763 |
| Start date: | 01-12-2021 |
| End date: | 30-11-2026 |
| Total budget - Public funding: | 1 499 961,00 Euro - 1 499 961,00 Euro |
Cordis data
Original description
Psychiatric disorders associated with changes in female sex hormones are a major public health issue and represent a unique opportunity to study the complex interplay between gender, sex and mental states. GASSP aims to understand how genetic and environmental markers can help identify women at risk of psychiatric disorders in relation to the menstrual cycle, childbirth and transition to menopause and improve the current approach to diagnosis, prevention and treatment. It takes a ground-breaking approach across diagnoses and life stages, rather than focussing on the current diagnostic labels that have limited clinical and biological validity. It seeks to characterise the largest cohort to date of women with psychiatric disorders temporally related with changes in sex hormones by leveraging new technologies a) to identify and reach sufferers, making it easier for them to participate in research b) to conduct sophisticated analyses, integrating detailed longitudinal clinical and psycho-social information with aggregated genome-wide data and functional annotations. GASSP is the first molecular genetic study of the psychiatric sensitivity to sex hormone changes. It has the potential to contribute to the de-stigmatization of mental disorders related to female reproduction by providing evidence-based, easy-to-understand information to the public, and addressing the gender gap in psychiatry highlighted by the European Commission and the World Health Organization.Status
SIGNEDCall topic
ERC-2020-STGUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
